Alexipharmic Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Alexipharmic Drugs Market Analysis
The alexipharmic drugs market studied was anticipated to grow with a CAGR of 4.9% during the forecast period. The major factor attributing to the growth of the market is a rise in the death rate due to drug overdoses like acetaminophen toxicity, cyanide poisoning, etc., around the world. Higher demand for opioid analgesics in the management of pain and benzodiazepines in psychotherapeutic treatment paved the way to severe adverse effects including death. As per the study report published by the MD Anderson Cancer Center in January 2020, chronic non-malignant pain is common in cancer patients and one in every three cancer patients was prescribed with opioids across the globe. Thus, acceptance and rising prescription of these potent medications fuel the growth of the alexipharmic drugs market.
Alexipharmic Drugs Market Trends
This section covers the major market trends shaping the Alexipharmic Drugs Market according to our research experts:
Opioid Overdose is Expected to Hold the Major Market Share in the Alexipharmic Drugs Market
Opioid overdose is expected to account for the largest market revenue share during the forecast period. This dominance is owing to increased adoption of opioids as primary line treatment by physicians and higher preference among the patients. Also, the higher incidences of deaths due to illicit consumption of Synthetic opioids increased demand for these products. Synthetic opioids, other than methadone such as tramadol and fentanyl result in more deaths than from any other type of opioid.
As per the factsheet published by the World Health Organization in August 2018, nearly 450,000 people died as a result of drug use in 2015. Among which about 160 thousand deaths were directly associated with drug use disorders and about 118 thousand with opioid use disorders. Also, the report states that an estimated 27 million people who suffered from opioid use disorders in 2016.
Furthermore, increased research activities to develop opioid reversal agents by the key players is likely to fuel the growth of the segment over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall alexipharmic drugs market owing to the rise in the number of cancers, plastic surgery, diabetic ulcer amputation cases, and others that necessitate the prescription of these drugs and driving the market growth in the region. As per the United States Department of Health and Human Services (HHS) report, about 70,237 drug overdose deaths were recorded in 2017 with a significant increase in deaths by 9.6% to that of 2016 in the United States. Also, the report emphasizes that opioids resulted in 47,600 deaths representing 67.8% of all drug overdose deaths in 2017. Thus, higher incidences of drug overdose deaths in the region demand immediate and effective alexipharmic drugs propelling the growth of the market in the region.
Alexipharmic Drugs Industry Overview
The alexipharmic drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are developing new products with lesser side effects and launching across the world. In October 2018, The National Agency for the Safety of Medicines and Healthcare Products (ANSM) granted marketing authorization to Ethypharm for its drug Baclocur in France for the first time in the world. Baclocur is a range of baclofen tablets in doses of 10, 20 and 40 mg prescribed for alcohol-dependent adult patients with high-risk alcohol consumption. Launch of such medication-assisted treatment (MAT) products will positively impact the market growth over the course of the forecast period. Some of the companies which are currently dominating the market are Bausch Health Companies Inc, Fresenius SE & Co. KGaA (Fresenius Kabi), Ethypharm S. A., Mylan N.V., and Emergent BioSolutions
Alexipharmic Drugs Market Leaders
-
Fresenius SE & Co. KGaA (Fresenius Kabi)
-
Mylan N.V.
-
Ethypharm S.A.
-
Emergent BioSolutions Inc
-
Bausch Health Companies Inc.
*Disclaimer: Major Players sorted in no particular order
Alexipharmic Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Dependence on Psychoactive Substances and Narcotic Drugs
- 4.2.2 Favorable Initiatives by Regulatory Agencies to Develop Medication-assisted Treatment (MAT) Products
-
4.3 Market Restraints
- 4.3.1 High Cost of Medication and Treatment Procedures
- 4.3.2 Increased Adoption of Alternative Treatments and Emerging Abuse-Deterrent Formulations (ADFs)
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Application
- 5.1.1 Alcholic Overdose
- 5.1.2 Opioid Overdose
- 5.1.3 Benzodiazepine Overdose
- 5.1.4 Cyanide Poisoning
- 5.1.5 Others
-
5.2 End-user
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United states
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bausch Health Companies Inc
- 6.1.2 Ethypharm S. A.
- 6.1.3 Fresenius SE & Co. KGaA (Fresenius Kabi)
- 6.1.4 Alkermes, Inc.
- 6.1.5 Mylan N.V.
- 6.1.6 B. Braun Melsungen AG
- 6.1.7 Emergent BioSolutions
- 6.1.8 Hikma Pharmaceuticals
- 6.1.9 SGPharma Pvt. Ltd.
- 6.1.10 Merck & Co., Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAlexipharmic Drugs Industry Segmentation
Alexipharmic drugs are medications that act as an antidote used to reverse or reduce the effects of a drug overdose, and drug poisoning. These are employed in an emergency shot to save lives quickly and can be used to defend against various types of microbial infections. As per the scope of the report, various alexipharmic drugs used in drug overdose and poisoning cases were described in detail.
| Application | Alcholic Overdose | |
| Opioid Overdose | ||
| Benzodiazepine Overdose | ||
| Cyanide Poisoning | ||
| Others | ||
| End-user | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Others | ||
| Geography | North America | United states |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Alexipharmic Drugs Market Research FAQs
What is the current Alexipharmic Drugs Market size?
The Alexipharmic Drugs Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)
Who are the key players in Alexipharmic Drugs Market?
Fresenius SE & Co. KGaA (Fresenius Kabi), Mylan N.V., Ethypharm S.A., Emergent BioSolutions Inc and Bausch Health Companies Inc. are the major companies operating in the Alexipharmic Drugs Market.
Which is the fastest growing region in Alexipharmic Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Alexipharmic Drugs Market?
In 2024, the North America accounts for the largest market share in Alexipharmic Drugs Market.
What years does this Alexipharmic Drugs Market cover?
The report covers the Alexipharmic Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Alexipharmic Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Alexipharmic Drugs Industry Report
Statistics for the 2024 Alexipharmic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Alexipharmic Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
